EGFR and non-small cell lung carcinoma: Additionally, the phase III MARIPOSA-2 study demonstrated that PFS was significantly longer for the combination of amivantamabe-lazertinibe and chemotherapy compared to chemotherapy alone in patients with EGFR-mutated advanced NSCLC who had progressed on or after osimertinib (median of 8.3 versus 4.2 months, respectively) (17).